"China Australia co construction, moving forward with a bright future"
On July 19th, the signing ceremony for the joint venture between Guangzhou Raytec Biotechnology Co., Ltd. and Capricornia Contact Lens Pty Ltd in Australia was successfully held in Wenjiang, Chengdu. Dr. Lin Yongliang, founder/chairman of Raytec Biotechnology, Xu Hao, co-founder/general manager, and Tony Capitano, chairman and general manager of Capricornia, Australia, attended the signing ceremony.
This signing ceremony was also witnessed by important guests from various sectors, including Dong Yong, Deputy Secretary of the Chengdu Wenjiang District Committee and Secretary of the Chengdu Medical City Party Working Committee; Li Zhenhua, Deputy Secretary of the Chengdu Medical City Party Working Committee and Director of the Management Committee; Mr.Rob Donelly, Commercial Minister of the Australian Embassy in China and General Manager of the Greater China Region of the Australian Trade and Investment Commission; Ms.Nina Dynon, Deputy Consul General of the Australian Consulate General in Chengdu; as well as representatives from the Chengdu Wenjiang District Foreign Affairs Office, Wenjiang District Economics and Information Bureau, Wenjiang District Investment Promotion Bureau, Wenjiang District Health Bureau, Wenjiang District New Economy and Science and Technology Bureau, Wenjiang District Market Regulation Bureau, Wenjiang District Federation of Industry and Commerce, Chengdu Medical City Management Committee, and other units, as well as representatives of project investors and cooperating partners.
At the conference, Dong Yong, Deputy Secretary of the Chengdu Wenjiang District Committee and Secretary of the Chengdu Medical City Party Working Committee, delivered a speech first and stated that Chengdu Medical City, as an important carrier of the medical and health industry in Chengdu, had gathered more than 400 upstream and downstream medical industry enterprises, including the Sichuan Branch of the National High-Performance Medical Device Innovation Center, the Sichuan Brain Science and Brain-like Intelligence Research Institute, WuXi AppTec, Kerui Pharmaceutical Group, and Bio-on Biotech, making it an excellent choice for Chinese and foreign biopharmaceutical companies to invest in.
Subsequently, Mr. Rob Donelly, Minister of Commerce of the Australian Embassy in China and General Manager of the Australian Trade and Investment Commission in Greater China, introduced us to Australia's investment environment and the current development status of China Australia cooperation. Mr. Rob Donelly stated that the successful cooperation between the two sides clearly demonstrates that Australia and China have a very strong and complementary economic and business partnership, which was formed decades ago. This year marks the 51st anniversary of the establishment of diplomatic relations between China and Australia, and our strong bilateral relationship is extremely deep, complex, and dynamic. We welcome Chinese companies to further invest in Australia, build stronger educational relationships and cooperation, and also hope that more Chinese tourists will come to our beautiful country for vacation.
Next, Lin Yongliang, founder and chairman of Raytec Biotechnology, and Mr., chairman of Capricornia, Australia Tony Capitano introduced the development history of Raytec Biotechnology and Capricornia respectively, and expressed his determination to accelerate investment in Wenjiang, Chengdu, as well as his firm confidence in establishing a joint venture company - Epicon(Chengdu) Medical Technology Co., Ltd. - to build a Chinese ophthalmology giant.
Mr. Lin Yongliang introduced that Raytec Biotechnology, founded in 2014, is a high-tech enterprise specializing in ophthalmic and regenerative medical materials, integrating research and development, production, and sales. The company boasts a highly educated technical team that has extensive experience in ophthalmic healthcare and multiple industry-academia-research technology platforms, including the "Regenerative Medical Materials Science and Technology Cooperation Base" jointly established with the National Biomedical Materials Engineering Technology Research Center of Sichuan University, and the "Shandong Provincial Engineering Research Center for Corneal Diseases" jointly established with Shandong Provincial Eye Hospital. The company's research and development products cover ocular surface, glaucoma, refractive errors, orthopedic regenerative materials, and other directions, and has been granted 16 patents (including 11 invention patents and 5 utility model patents). The technical level of multiple products is domestically leading and world-class.
Meanwhile, Mr. Lin Yongliang also stated that Raytec Biotechnology will provide funding, venue, and personnel support for this cooperation project to assist in completing Epicon A ®” Registering, producing, and selling in China, creating a joint venture to become a domestic platform for comprehensive cooperation between Raytec Biotechnology and Capricornia in the field of ophthalmology.
Mr. Tony Capitano, on the other hand, stated that Capricornia and Raytec Biotechnology are committed to excellence together, and I believe this will earn us a trustworthy reputation. Our goal has always been to provide patients with safe, effective, and innovative eye care products to improve their daily lives. Australia's advanced ophthalmic technology perfectly complements China's strong supply chain capabilities and market size, enabling the joint venture to complement each other's strengths. I believe that the establishment of a joint venture will help improve the eye health level of Chinese patients and promote the development of the ophthalmic medical industry in China.
Subsequently, the signing ceremony ushered in the most important part of the day - signing. Mr. Xu Hao, co-founder/general manager of Raytec Biotechnology, and Mr., chairman of Capricornia Tony Capitano successfully signed contracts on behalf of Guangzhou Raytec Biotechnology Co., Ltd. and Capricornia Contact Lens Pty Ltd. in Australia, opening a new chapter in their cooperation.
After this signing, Raytec Biotechnology will officially establish a joint venture with Capricornia, Australia, in Wenjiang - Epicon(Chengdu) Medical Technology Co., Ltd. Epicon will provide a complete set of innovative solutions for medical equipment in the field of ophthalmology, mainly involving the prevention and control of adolescent myopia, adult vision correction and treatment of ocular surface diseases, and a complete set of contact lens care products. In 2025, the first domestically approved scleral lens will be produced domestically and its large-scale production will be carried out in Wenjiang, Chengdu. At the same time, Epicon will gradually introduce more international advanced ophthalmic products from Capricornia, including defocus soft lenses, soft astigmatism, and multifocal contact lenses, and establish a globally leading automated production line.
After the conference, Mr. Xu Hao, co-founder/general manager of Raytec Biotechnology and chairman of Epicon(Chengdu) Medical Technology Co., Ltd., gave an interview to media outlets such as Chengdu TV and Wenjiang District Integrated Media Center, mentioning the reasons and significance of the cooperation project settling in Wenjiang, Chengdu. Mr. Xu Hao stated that the reason for settling in Wenjiang, Chengdu is firstly due to the highly professional services and good medical supply chain of Chengdu Wenjiang Medical City. Secondly, Chengdu Wenjiang has a complete medical and university city that provides high-quality talents. Thirdly, and most importantly, the business environment in Chengdu is very good. Just one week before the signing ceremony, Sichuan University West China Hospital had already issued three prescriptions. Mr. Xu Hao also expressed great confidence in the settlement of the cooperative project in Chengdu Wenjiang Chengdu Medical City, where he will establish a visual medical center. It is expected to achieve an annual output value of 600 million yuan and an annual tax payment of 60 million yuan in 2 years, and maintain an annual growth rate of 30%.
The establishment of the joint venture company lays the foundation for the international advanced ophthalmic medical devices to enter China and gradually achieve localization. The successful signing of a contract between Chinese and Australian enterprises has brought new opportunities for cooperation in the field of ophthalmology and medical care between the two countries. Both parties will jointly focus on the research and innovation of optometry products, committed to promoting the promotion and application of international advanced ophthalmic medical devices in China, continuously improving people's eye health level, and making positive contributions to the development of ophthalmic medical industry.